MolPort-001-684-488

[{"orgOrder":0,"company":"Alzheimer's Disease Cooperative Study","sponsor":"National Institute on Aging | VA Puget Sound Health Care System | Alzheimer's Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Phase II","graph3":"Alzheimer's Disease Cooperative Study","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzheimer's Disease Cooperative Study \/ National Institute on Aging | VA Puget Sound Health Care System | Alzheimer's Association","highestDevelopmentStatusID":"8","companyTruncated":"Alzheimer's Disease Cooperative Study \/ National Institute on Aging | VA Puget Sound Health Care System | Alzheimer's Association"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Lung Association","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Lung Association","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Lung Association"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"VA Puget Sound Health Care System | Madigan Army Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Phase IV","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ VA Puget Sound Health Care System | Madigan Army Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ VA Puget Sound Health Care System | Madigan Army Medical Center"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"National Institute on Aging | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Neurology","graph2":"Undisclosed","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Aging | VA Puget Sound Health Care System","highestDevelopmentStatusID":"1","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Aging | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"US Department of Defense | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Lung Association | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Lung Association | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Lung Association | Pfizer Inc"},{"orgOrder":0,"company":"VA Puget Sound Health Care System","sponsor":"University of Washington | VA Mental Illness Research, Education and Clinical Centers","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"VA Puget Sound Health Care System","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Puget Sound Health Care System \/ University of Washington | VA Mental Illness Research, Education and Clinical Centers","highestDevelopmentStatusID":"11","companyTruncated":"VA Puget Sound Health Care System \/ University of Washington | VA Mental Illness Research, Education and Clinical Centers"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"US Department of Defense | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System","highestDevelopmentStatusID":"1","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"}]

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

26 API Suppliers, 16 USDMF, 1 CEP/COS, 2 EU WC, 8 NDC API, 12 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

13 Intermediate Suppliers

13 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

97 FDF Dossiers, 57 FDA Orange Book, 3 Europe, 6 Canada, 16 Australia, 3 South Africa, 12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 1MG BASE, CAPSULE;ORAL - EQ 2MG BASE, CAPSULE;ORAL - EQ 5MG BASE

RELATED EXCIPIENT COMPANIES

5 SPI Pharma, 9 DKSH, 3 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 BASF, 5 DFE Pharma, 1 Finar, 5 Gangwal Chemicals, 1 Ideal Cures, 2 Ingredion Pharma Solutions, 14 Kerry, 1 Keval Exports, 3 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 2 Prachin Chemical, 1 Qualicaps, 15 Roquette, 2 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 2 Silverline Chemicals, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

41 Fillers, Diluents & Binders, 24 Direct Compression, 19 Thickeners and Stabilizers, 18 Granulation, 12 Lubricants & Glidants, 11 Coating Systems & Additives, 10 Co-Processed Excipients, 9 Taste Masking, 8 Empty Capsules, 7 Disintegrants & Superdisintegrants, 6 Chewable & Orodispersible Aids, 5 Film Formers & Plasticizers, 4 Topical, 4 Emulsifying Agents, 4 Controlled & Modified Release, 3 Coloring Agents, 3 Parenteral, 2 Solubilizers, 2 Rheology Modifiers, 1 API Stability Enhancers, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

10 News #PharmaBuzz

10 News #PharmaBuzz

GLOBAL SALES INFORMATION

15 US Medicaid Prescriptions, 6 Regulatory FDF Prices

MARKET PLACE

7 APIs, 1 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 2 JP

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Granules India Limited

India

CPhI India

Attending

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Lead Product(s) : Prazosin Hydrochloride

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Approved FDF

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Granules Pharmaceuticals Inc., Receives ANDA Approval for Prazosin Hydrochloride Capsules

Details : Prazosin HCl inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting effect of catecholamines on the vessels, leading to peripheral blood vessel dilation.

Product Name : Miniplus-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 28, 2021

Lead Product(s) : Prazosin Hydrochloride

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Sponsor : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

Alembic Pharmaceuticals Limited

India

Country

AIChE Annual Meeting

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for MolPort-001-684-488